A5047831501- Lung Cancer Treatments and Mutations
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Palliative Care and End-of-Life Issues
- Lung Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Colorectal and Anal Carcinomas
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Research Studies
- Clinical practice guidelines implementation
- Global Cancer Incidence and Screening
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Primary Care and Health Outcomes
- Blood transfusion and management
- Healthcare Policy and Management
- Neutropenia and Cancer Infections
- RNA modifications and cancer
- Bladder and Urothelial Cancer Treatments
- Patient Satisfaction in Healthcare
- Cancer Diagnosis and Treatment
- Renal and related cancers
- Neuroendocrine Tumor Research Advances
- Management of metastatic bone disease
- Cancer Treatment and Pharmacology
University of Pennsylvania
2020-2024
Abramson Cancer Center
2024
Fox Chase Cancer Center
2018-2024
Penn Center for AIDS Research
2024
University of Pennsylvania Health System
2024
Hospital of the University of Pennsylvania
2022-2023
Presbyterian Hospital
2022
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management patients with SCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. This selection the journal focuses on metastatic (known as extensive-stage) which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms prolong survival most extensive-stage disease. Smoking cessation counseling intervention...
The availability of targeted therapies has transformed the management advanced NSCLC; however, most patients do not undergo guideline-recommended tumor genotyping. impact plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspected NSCLC largely been unexplored.We a prospective cohort study lung cancer on basis cross-sectional imaging results. Blood from time was sequenced using commercially available 74-gene panel. primary outcome measure to...
Importance Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often used for patients with locally advanced head neck cancer who ineligible cisplatin. There no prospective head-to-head data comparing cetuximab-based regimens radiosensitization. Objective To compare survival CRT in squamous cell carcinoma (HNSCC). Design, Setting, Participants This cohort study included US veterans received a diagnosis of HNSCC between January 2006 December 2020 were treated systemic therapy...
Abstract Background In RAS-mutant tumors, combined MEK and autophagy inhibition using chloroquine demonstrated synthetic lethality in preclinical studies. This phase II trial evaluated the safety activity of inhibitor binimetinib with hydroxychloroquine (HCQ) patients advanced KRAS-mutant non-small cell lung cancer (NSCLC). Methods Eligibility criteria included NSCLC, progression after first-line therapy, ECOG PS 0-1, adequate end-organ function. Binimetinib 45 mg was administered orally...
Immune checkpoint inhibition (ICI) is a frontline treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but questions remain surrounding optimal duration of therapy, benefits risks ICI rechallenge, efficacy in first vs subsequent lines therapy.
Studies suggest that many emergency department (ED) visits and hospitalizations for patients with cancer may be preventable. The Centers Medicare & Medicaid Services has implemented changes to the hospital outpatient reporting program targets acute care in-treatment preventable conditions. Oncology urgent centers aim streamline patient care. Our center developed an called direct referral unit in 2011.
Immune checkpoint inhibitors (CPIs) are now part of standard therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) because improved outcomes compared chemotherapy in clinical trials. However, data on HNSCC the general population who treated CPIs remain limited.To assess response rates, survival outcomes, associations key covariates a large, contemporary cohort mucosal were without chemotherapy.This retrospective study included older than 18 years...
TPS8664 Background: The development of targeted therapies has changed the treatment paradigm for non–small cell lung cancer (NSCLC). With growing number FDA approved therapies, current NCCN guidelines recommend comprehensive molecular genotyping prior to first line (1L) therapy all newly diagnosed patients with metastatic non-squamous (mNSq) NSCLC enable delivery personalized therapy. Based on work that found improved detection clinically actionable alterations through concurrent plasma (P)...
8551 Background: Immune checkpoint inhibitors (ICIs) have improved survival outcomes in patients (pts) with advanced non–small cell lung cancer (NSCLC). Although pivotal trials stipulated ICI therapy for up to 2 years, many pts clinical practice continue beyond years. Data on long-term toxicities developing after more than years of treatment are very limited. Methods: A single-institution retrospective analysis including who received greater recurrent/metastatic NSCLC from 01/2012-01/2023...
77 Background: Patients with suspected cancer often face challenges navigating complex health systems, resulting in delays diagnosis and time to treatment, which are associated adverse outcomes patient dissatisfaction. To improve access bridge this healthcare gap, the Cancer Diagnostic (CDx) clinic was established streamline evaluation for patients a new cancer. The CDx prioritizes expedited evaluation, timely accurate diagnostic testing, transition of care subspecialty Oncologists,...
169 Background: Cancer-related financial hardship is associated with treatment delays, non-adherence and adverse survival outcomes. Racial/ethnic minorities low-income households are disproportionately impacted by toxicity. The Comprehensive Score for Financial Toxicity (COST) measure used to toxicity in research but has not been validated low-income, racially diverse cancer patient populations. Methods: We conducted this study at a large urban medical center from January-August 2023....
<h3>Background</h3> Transfusions of packed red blood cells (PRBC) have been postulated to be immunosuppressive, an effect known as transfusion-related immunomodulation (TRIM). TRIM is thought a result the immunosuppressive and pro inflammatory effects residual leukocytes, apoptotic cells, mediators, micro particles free hemoglobin<sup>1</sup> Prior studies shown negative association between perioperative PRBC transfusions overall mortality in multiple malignancies.<sup>2–13</sup> To date...
7 Background: Studies suggest that many Emergency Department (ED) visits and hospitalizations for cancer patients may be preventable. CMS has made changes to the hospital outpatient reporting program (OP-35) targeting ED admissions in treatment preventable conditions. Oncologic urgent care centers aim streamline this population. Fox Chase Cancer Center (FCCC) developed an center called Direct Referral Unit (DRU) July 2011. We sought assess impact of DRU on utilization. Methods: abstracted...
381 Background: With the growing complexity and cost of cancer care, adoption oncology pathway tools as clinical decision support (CDS) has increased at point care. These have been shown to improve care quality, reduce variations in healthcare costs. Flatiron Assist (FA) is a customizable CDS tool that embedded electronic health record (EHR) facilitate selection documentation National Comprehensive Cancer Network (NCCN) guideline concordant treatment regimens. The time burden engaging with...
e21054 Background: The patterns of failure (POF) for patients (pts) with mNSCLC treated immunotherapy are not well established. These POF inform treatment decisions and may identify candidates radiotherapy (RT). primary objective this study was to establish the in first line pembrolizumab, frequency oligoprogression (OPD), characterize use RT OPD. Methods: We retrospectively identified pts who received pembrolizumab +/- chemotherapy between January 2015 – 2021 at a single institution....
1578 Background: Clinical pathways have emerged as a strategy to provide value-based care by reducing treatment variation across oncology practice. Despite evidence for cost reduction and improved patient outcomes, adoption of clinical has met resistance in the community given concerns regarding impact on workflow, cost. Flatiron Assist, an EMR based tool, is promising solution minimizing workflow friction proving novel, streamlined user interface. Methods: The Abramson Cancer Center at...
e24165 Background: Head and neck cancer (HNC) treatment with chemoradiation therapy (CRT) is highly morbid. Patients develop significant symptoms including severe pain, dysphagia, malnutrition resulting in poor quality of life (QOL), frequent hospitalizations, high rates depression. Although integration palliative care (PC) teams into the incurable cancers has resulted improved QOL, less known about its patients receiving curative-intent treatments. We sought to characterize use PC during...